/

Società

Ca

Non verificato

CatalYm

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

12 comunicati stampa

Guarda tutti i comunicati

24/10/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Fiere

Industria

CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026

Fonte

Emittente

1.00

0

06/10/2026

Eventi

Industria

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026

Fonte

Emittente

1.00

0

09/06/2026

Mercato del lavoro

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

CatalYm Appoints Peter Garcia as Chief Financial Officer

Fonte

Emittente

1.00

0

07/04/2026

Industria

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

Fonte

Emittente

1.00

0

02/12/2025

Industria

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC

Fonte

Emittente

1.00

0

17/10/2025

Oncologia

Salute

Biotecnologia

Sanità

Medicina - Varie

Farmaceutica

Eventi

Fiere

Industria

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

Fonte

Emittente

1.00

0

30/09/2025

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

Industria

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC

Fonte

Emittente

1.00

0

22/09/2025

Fiere

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO

Fonte

Emittente

1.00

0

09/01/2025

Mercato del lavoro

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab

Fonte

Emittente

1.00

0

11/12/2024

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Industria

CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0